MDxHealth and LI PATH Announce Marketing Agreement for ConfirmMDx for Prostate Cancer

MDxHealth and LI PATH Announce Marketing Agreement for ConfirmMDx for Prostate Cancer  IRVINE, Calif.  and  HERSTAL,  Belgium,  April 2,  2014  (GLOBE  NEWSWIRE)  --  MDxHealth SA (NYSE  Euronext: MDXH),  a leading  molecular diagnostic  company  that develops and commercializes epigenetic tests to improve the diagnosis and treatment of  cancer patients,  today announced  that it  has entered  into  a  co-marketing agreement with LI PATH  (Long Island Pathology, Inc.) to  promote  MDxHealth's ConfirmMDx^®  for Prostate  Cancer test.  LI PATH  is a  high-end,  full-service independent  anatomic  and  clinical  pathology  laboratory  that  serves the New York City metropolitan area. The agreement expands MDxHealth's access to urologists in the highly populated New York and New Jersey region.  "Our goal is to be the premier laboratory serving the urology community in the New York City area,  and offering the most  advanced molecular testing to  our  urology clients is  an important part  of that equation,"  stated Ken  Cerney,  Chief Executive Officer of LI PATH. "The ConfirmMDx for Prostate Cancer test provides actionable information to help urologists better stratify patients at risk for undetected prostate cancer and guide the decision for repeat  biopsy.  The addition ConfirmMDx  to our portfolio  of tests enhances  our ability  to  serve our clients."  "We are excited to announce our strategic partnership with LI PATH, recognized as a  leading anatomic  and  clinical pathology  laboratory  in the  New  York  metropolitan region. With their extensive client base and strong  reputation,  the partnership further expands access  to our ConfirmMDx for Prostate  Cancer  test within this  important geographic  region," said  Dr. Jan  Groen, CEO  of  MDxHealth. "It is rewarding to  partner with progressive thinking  laboratory  professionals like LI PATH, who are focused on leveraging molecular diagnostic tests to deliver the highest quality patient care."  About ConfirmMDx® for Prostate Cancer Over 975,000 American men receive a negative prostate biopsy result each year, though approximately 25% of these men may still harbor occult prostate cancer. This  well-documented  risk  of  undetected  cancer,  often  with   clinically  significant Gleason  scores, leads  to a  high rate  of repeat  biopsies  with  greater than  40%  of men  receiving  at least  one  repeat biopsy,  and  many  receiving a 3rd and 4th biopsy. Today's gold standard diagnostic approach  is  the prostate biopsy  procedure, collecting 10-12  needle core biopsy  samples;  however this sampling represents less than 1% of a man's prostate. ConfirmMDx for Prostate  Cancer is  an epigenetic  assay to  help urologists  distinguish  patients who have a true-negative biopsy from those at risk for occult cancer. The test is able  to detect an epigenetic  field effect or "halo"  associated  with the cancerization process at the DNA level. This molecular "halo" around a cancer lesion can  be present despite having  a normal appearance under  the  microscope. The test helps urologists rule out prostate cancer-free men  from  undergoing unnecessary repeat biopsies and rule in high-risk patients who  may  require repeat biopsies and potential treatment.  About LI PATH LI PATH is a premier diagnostic and consultative anatomical laboratory located in East Setauket, New  York that has been  serving the regional community  for  nearly 20  years.LI PATH  is dedicated  to providing  top-level  diagnostic  pathology and clinical services in a cost effective and efficient manner. The laboratory's pathologists are  certified by  the American  Board of  Pathology  with  multiple  areas  of  sub-specialties  and  are  active  members  of  the  community.  For  additional  information  about  LI  PATH's  clinical  and  AP  diagnostic offerings, please visit  About MDxHealth MDxHealth is a molecular diagnostics company that develops and  commercializes  advanced epigenetic tests for cancer assessment and the personalized treatment of patients. MDxHealth  helps to address  a large and  growing unmet  medical  need for better cancer diagnosis and treatment information. The company has  a  proprietary platform and a strong  epigenetic product pipeline focused on  the  development of products for  prostate, brain, bladder  and lung cancers.  For  more  information   visit   and   follow  us   on   Twitter  For more information:  Dr. Jan Groen, CEO  Mike Sinclair         Len Hall MDxHealth           Halsin Partners       Allen & Caron, Inc US: +1 949 812 6979 UK: +44 20 7318 2955 US: +1 949 474 4300 BE: +32 4 364 20 70 Cell: +44 7968 022075    This press  release contains  forward-looking  statements and  estimates  with  respect to the anticipated future performance  of MDxHealth and the market  in  which it operates. Such statements and estimates are based on assumptions  and  assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable  but may  not prove to  be correct.  Actual events  are  difficult to predict, may  depend upon factors that  are beyond the  company's  control, and  may turn  out to  be materially  different. MDxHealth  expressly  disclaims any obligation to update any such forward-looking statements in this release to reflect any change in  its expectations with regard thereto or  any  change in events, conditions or circumstances  on which any such statement  is  based unless  required by  law  or regulation.  This  press release  does  not  constitute an offer or  invitation for the sale  or purchase of securities  or  assets of MDxHealth  in any jurisdiction.  No securities of  MDxHealth may  be  offered or sold within the United  States without registration under the  U.S.  Securities Act  of  1933, as  amended,  or  in compliance  with  an  exemption  therefrom, and in accordance with any applicable U.S. securities laws.  NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are  trademarks  or registered trademarks  of MDxHealth  SA. All other  trademarks and  service  marks are the property of their respective owners.  To access the PDF version, please click here  HUG#1773399